特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
283286

プレフィルドシリンジの世界市場:2020-2030年

Prefilled Syringes Market (5th Edition), 2020-2030

出版日: | 発行: Roots Analysis | ページ情報: 英文 554 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
プレフィルドシリンジの世界市場:2020-2030年
出版日: 2020年01月31日
発行: Roots Analysis
ページ情報: 英文 554 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

自己投与可能な慢性疾患治療薬の開発と商業化は、患者が負担する医療費だけでなく、服薬コンプライアンスの面にも大きなプラスの影響を与えています。慢性疾患患者の数が増加する中で、利便性が高く、患者に優しい薬物送達ソリューションの需要が高まっています。

当レポートでは、世界のプレフィルドシリンジ (薬液充填済み注射器) の市場を調査し、市場の定義と概要、製品開発の経緯、製品の種類と概要、上市済み製品、開発中の製品、製造業者のリスト、関連法規制、コンビネーション薬の動向、技術開発の動向、診療区分・バレル材料・チャンバーシステム・薬剤分子・地域/主要国など各種区分別の市場規模の予測、市場成長への各種影響因子の分析、将来の展望などをまとめています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 プレフィルドシリンジ:イントロダクション

  • 本章の概要
  • プレフィルドシリンジの歴史
  • 従来型の注射装置に勝るプレフィルドシリンジのメリット
  • プレフィルドシリンジのコンポーネント
  • プレフィルドシリンジの分類
  • プレフィルドシリンジ設計の重要な特性
  • プレフィルドシリンジの製造
  • プレフィルドシリンジの将来

第4章 プレフィルドシリンジ:市場概要

  • 本章の概要
  • 上市済み製品・開発中の製品のリスト:各種区分別
  • ディベロッパーリスト
  • 技術開発動向

第5章 製品の競争力

第6章 プレフィルドシリンジの製造業者:地域別

第7章 針刺し事故

  • 本章の概要
  • 発生率・関連の経済的負担
  • 法規制
  • 安全メカニズム

第8章 法規制環境:地域別

第9章 プレフィルドシリンジコンビネーション製品:市場概要

  • 本章の概要
  • コンビネーション製品:承認済み薬のリスト
  • コンビネーション製品:開発中の薬剤のリスト
  • コンビネーション製品:ディベロッパーリスト
  • 主要薬剤
  • その他の利用可能な薬剤
  • 一般的な薬剤:ケーススタディ
    • HUMIRAR (アダリムマブ):AbbVie / エーザイ
    • EnbrelR (エタネルセプト):Amgen / Pfizer / 武田薬品工業

第10章 主要診療エリア

  • 本章の概要
    • 自己免疫疾患
    • 感染症
    • 神経系疾患
    • 代謝性疾患

第11章 薬剤候補・潜在的パートナー

  • 本章の概要

第12章 大手事業者のイニチアチブ:コンビネーション製品・その他類似薬剤候補

第13章 専用プレフィルドシリンジ

  • 本章の概要
  • フラッシュシリンジ
  • 希釈剤シリンジ
  • 造影剤シリンジ

第14章 近年の技術開発の動向・新しい用途

第15章 市場規模の予測・市場機会の分析

  • 本章の概要
  • 調査範囲・調査手法
  • 世界市場の予測
    • 診療区分別
      • 自己免疫疾患
      • 感染症
      • 神経系疾患
      • 血液疾患
      • 精神疾患
      • 呼吸器疾患
      • 心臓血管疾患
      • 代謝性疾患
      • 眼科疾患
      • 整形外科疾患
      • その他
    • バレル材料タイプ別
      • ガラス
      • プラスチック
    • チャンバーシステムタイプ別
      • シングルチャンバー
      • デュアルチャンバー
    • 薬剤分子タイプ別
      • 抗体
      • タンパク質
      • ペプチド
      • 低分子
      • ワクチン
    • 地域別
    • 専用シリンジ別

第16章 成長推進因子

第17章 SWOT分析

第18章 プレフィルドシリンジコンポーネント製造業者

第19章 フィル&フィニッシュサービスプロバイダー

第20章 ケーススタディ:オートインジェクター

第21章 総論

第22章 インタビュー全文

第23章 付録:図表

第24章 付録:企業リスト

図表

List Of Figuers

  • Figure 3.1 Glass Barrel Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.2 Plastic Barrel Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.3 Critical Design Parameters of Prefilled Syringes
  • Figure 3.4 Prefilled Syringe Manufacturing: Common Process
  • Figure 4.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
  • Figure 4.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Figure 4.3 Prefilled Syringes: Distribution by Type of Needle System
  • Figure 4.4 Prefilled Syringes: Distribution by Device Capacity
  • Figure 4.5 Prefilled Syringe Developers: Distribution by Year of Establishment
  • Figure 4.6 Prefilled Syringe Developers: Distribution by Company Size
  • Figure 4.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
  • Figure 4.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
  • Figure 4.9 Technological Evolution of Prefilled Syringes
  • Figure 5.1 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
  • Figure 5.2 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
  • Figure 6.1 BD Medical: Annual Revenues, FY 2010-11 - FY 2017-18 (USD Billion)
  • Figure 6.2 BD Medical: Revenue Distribution by Sub-Segments, FY 2017-18 (USD Billion)
  • Figure 6.3 West Pharmaceutical: Annual Revenues, 2011 - H1 2019 (USD Million)
  • Figure 6.4 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
  • Figure 6.5 West Pharmaceutical: Revenue Distribution by Region, 2018 (USD Million)
  • Figure 6.6 Gerresheimer: Annual Revenues, FY 2010-11 - H1 2018-19 (EUR Million)
  • Figure 6.7 Gerresheimer: Revenue Distribution by Business Divisions, FY 2017-18 (EUR Million)
  • Figure 6.8 Gerresheimer: Revenue Distribution by Region, FY 2017-18 (EUR Million)
  • Figure 6.9 SCHOTT: Annual Revenues, FY 2012-13 - FY 2018-19 (EUR Million)
  • Figure 6.10 SCHOTT: Revenue Distribution by Geography, FY 2018-19 (EUR Million)
  • Figure 6.11 Nipro: Annual Revenues, FY 2011-12 - FY 2018-19 (JPY Billion)
  • Figure 6.12 Nipro: Revenue Distribution by Business Divisions, FY 2018-19 (JPY Billion)
  • Figure 6.13 Nipro: Revenue Distribution by Region, FY 2018-19 (JPY Billion)
  • Figure 6.14 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
  • Figure 6.15 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
  • Figure 6.16 Terumo: Annual Revenues, FY 2011-12 - FY 2018-19 (JPY Billion)
  • Figure 6.17 Terumo: Revenue Distribution by Business Divisions, FY 2017-18 (JPY Billion)
  • Figure 6.18 Terumo: Revenue Distribution by Region, FY 2017-18 (JPY Billion)
  • Figure 7.1 Worldwide Evolution in Healthcare Safety Legislation
  • Figure 8.1 Global Regulations Related to Prefilled Syringes
  • Figure 8.2 Approval Pathway for Combination Products in the US
  • Figure 8.3 Approval Pathway for Combination Products in Canada
  • Figure 8.4 Pharmaceuticals and Medical Devices Agency: Review / Approval Process
  • Figure 8.5 Approval Pathway for Combination Products in China
  • Figure 9.1 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
  • Figure 9.2 Approved Prefilled Syringe Combination Products: Distribution by Approval Year
  • Figure 9.3 Approved Prefilled Syringe Combination Products: Distribution by Approval Geographies
  • Figure 9.4 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
  • Figure 9.5 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
  • Figure 9.6 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
  • Figure 9.7 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
  • Figure 9.8 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
  • Figure 9.9 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
  • Figure 9.10 Approved Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
  • Figure 9.11 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
  • Figure 9.12 Prefilled Syringe Combination Product Developers: Distribution by Company Size
  • Figure 9.13 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
  • Figure 9.14 Sales of Leading Drugs Available in Prefilled Syringes, 2018 (USD Billion)
  • Figure 9.15 HUMIRA®: Approval Timeline (US, EU and Japan)
  • Figure 9.16 HUMIRA®: Approval Timeline for Different Dosage Forms (US and EU)
  • Figure 9.17 HUMIRA®: Annual Sales, 2003-Q3 2019 (USD Million)
  • Figure 9.18Enbrel®: Approval Timeline (US and EU)
  • Figure 9.19 Enbrel®: Approval Timeline for Different Dosage Forms (US and EU)
  • Figure 9.20 Enbrel®: Annual Sales in the US and Canada, 2002-2018 (USD Million)
  • Figure 9.21 Enbrel®: Annual Sales outside US and Canada, 2010-2018 (USD Million)
  • Figure 12.1 Big Pharma Initiatives: Analysis by Therapeutic Area
  • Figure 12.2 Big Pharma Initiatives: Autoimmune Disorders
  • Figure 12.3 Big Pharma Initiatives for Autoimmune Disorders: Analysis by Target Indication
  • Figure 12.4 Big Pharma Initiatives: Infectious Diseases
  • Figure 12.5 Big Pharma Initiatives for Infectious Diseases: Analysis by Target Indication
  • Figure 12.6 Big Pharma Initiatives: Neurological Disorders
  • Figure 12.7 Big Pharma Initiatives for Neurological Disorders: Analysis by Target Indication
  • Figure 12.8 Big Pharma Initiatives: Oncologic Disorders
  • Figure 12.9 Big Pharma Initiatives for Oncologic Disorders: Analysis by Target Indication
  • Figure 12.10 Big Pharma Initiatives: Orthopedic Disorders
  • Figure 12.11 Big Pharma Initiatives for Orthopedic Disorders: Analysis by Target Indication
  • Figure 12.12 Big Pharma Initiatives: Metabolic Disorders
  • Figure 12.13 Big Pharma Initiatives for Metabolic Disorders: Analysis by Target Indication
  • Figure 12.14 Big Pharma Initiatives: Inflammatory Disorders
  • Figure 12.15 Big Pharma Initiatives for Inflammatory Disorders: Analysis by Target Indication
  • Figure 12.16 Big Pharma Initiatives: Other Disorders
  • Figure 12.17 Big Pharma Initiatives: Analysis by Type of Drug Molecule
  • Figure 12.18 Big Pharma Initiatives: Analysis by Antibodies
  • Figure 12.19 Big Pharma Initiatives: Analysis by Proteins
  • Figure 12.20 Big Pharma Initiatives: Analysis by Vaccines
  • Figure 12.21 Big Pharma Initiatives: Analysis by Other Molecules
  • Figure 15.1 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
  • Figure 15.2 Global Prefilled Syringes Market, 2020-2030 (Million Units)
  • Figure 15.3 Global Prefilled Syringes Market, 2020-2030 (USD Million)
  • Figure 15.4 Prefilled Syringes Market: Distribution by Therapeutic Area, 2020-2030
  • Figure 15.5 Prefilled Syringes Market: Share of Autoimmune Disorders, 2020-2030 (Million Units)
  • Figure 15.6 Prefilled Syringes Market: Share of Autoimmune Disorders, 2020-2030 (USD Million)
  • Figure 15.7 Prefilled Syringes Market: Share of Infectious Diseases, 2020-2030 (Million Units)
  • Figure 15.8 Prefilled Syringes Market: Share of Infectious Diseases, 2020-2030 (USD Million)
  • Figure 15.9 Prefilled Syringes Market: Share of Neurological Disorders, 2020-2030 (Million Units)
  • Figure 15.10 Prefilled Syringes Market: Share of Neurological Disorders, 2020-2030 (USD Million)
  • Figure 15.11 Prefilled Syringes Market: Share of Blood Disorders, 2020-2030 (Million Units)
  • Figure 15.12 Prefilled Syringes Market: Share of Blood Disorders, 2020-2030 (USD Million)
  • Figure 15.13 Prefilled Syringes Market: Share of Oncological Disorders, 2020-2030 (Million Units)
  • Figure 15.14 Prefilled Syringes Market: Share of Oncological Disorders, 2020-2030 (USD Million)
  • Figure 15.15 Prefilled Syringes Market: Share of Psychiatric Diseases, 2020-2030 (Million Units)
  • Figure 15.16 Prefilled Syringes Market: Share of Psychiatric Diseases, 2020-2030 (USD Million)
  • Figure 15.17 Prefilled Syringes Market: Share of Respiratory Disorders, 2020-2030 (Million Units)
  • Figure 15.18 Prefilled Syringes Market: Share of Respiratory Disorders, 2020-2030 (USD Million)
  • Figure 15.19 Prefilled Syringes Market: Share of Cardiovascular Disorders, 2020-2030 (Million Units)
  • Figure 15.20 Prefilled Syringes Market: Share of Cardiovascular Disorders, 2020-2030 (USD Million)
  • Figure 15.21 Prefilled Syringes Market: Share of Metabolic Disorders, 2020-2030 (Million Units)
  • Figure 15.22 Prefilled Syringes Market: Share of Metabolic Disorders, 2020-2030 (USD Million)
  • Figure 15.23 Prefilled Syringes Market: Share of Ophthalmic Disorder, 2020-2030 (Million Units)
  • Figure 15.24 Prefilled Syringes Market: Share of Ophthalmic Disorders, 2020-2030 (USD Million)
  • Figure 15.25 Prefilled Syringes Market: Share of Orthopedic Disorders, 2020-2030 (Million Units)
  • Figure 15.26 Prefilled Syringes Market: Share of Orthopedic Disorders, 2020-2030 (USD Million)
  • Figure 15.28 Prefilled Syringes Market: Share of Other Diseases, 2020-2030 (Million Units)
  • Figure 15.29 Prefilled Syringes Market: Share of Other Diseases, 2020-2030 (USD Million)
  • Figure 15.30 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
  • Figure 15.31 Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.32 Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.33 Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.34 Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.35 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
  • Figure 15.36 Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.37 Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.38 Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.39 Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.40 Prefilled Syringes Market: Distribution by Type of Drug Molecule, 2020, 2025 and 2030 (USD Million)
  • Figure 15.41 Prefilled Syringes Market: Share of Antibodies, 2020-2030 (Million Units)
  • Figure 15.42 Prefilled Syringes Market: Share of Antibodies, 2020-2030 (USD Million)
  • Figure 15.43 Prefilled Syringes Market: Share of Proteins, 2020-2030 (Million Units)
  • Figure 15.44 Prefilled Syringes Market: Share of Proteins, 2020-2030 (USD Million)
  • Figure 15.45 Prefilled Syringes Market: Share of Peptides, 2020-2030 (Million Units)
  • Figure 15.46 Prefilled Syringes Market: Share of Peptides, 2020-2030 (USD Million)
  • Figure 15.47 Prefilled Syringes Market: Share of Small Molecules, 2020-2030 (Million Units)
  • Figure 15.48 Prefilled Syringes Market: Share of Small Molecules, 2020-2030 (USD Million)
  • Figure 15.49 Prefilled Syringes Market: Share of Vaccines, 2020-2030 (Million Units)
  • Figure 15.50 Prefilled Syringes Market: Share of Vaccines, 2020-2030 (USD Million)
  • Figure 15.51 Prefilled Syringes Market: Distribution by Geographical Regions (USD Million)
  • Figure 15.52 Prefilled Syringes Market: Share of North America, 2020-2030 (Million Units)
  • Figure 15.53 Prefilled Syringes Market: Share of North America, 2020-2030 (USD Million)
  • Figure 15.54 Prefilled Syringes Market: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.55 Prefilled Syringes Market: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.56 Prefilled Syringes Market: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.57 Prefilled Syringes Market: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.58 Prefilled Syringes Market: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.59 Prefilled Syringes Market: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.60 Prefilled Syringes Market: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.61 Prefilled Syringes Market: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.62 Prefilled Syringes Market: Distribution by Specialty Syringes, 2020-2030 (Million Units)
  • Figure 15.63 Prefilled Syringes Market: Distribution by Specialty Syringes, 2020-2030 (USD Million)
  • Figure 15.64 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.65 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.66 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.67 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.68 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.69 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.70 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.71 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.72 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, 2020-2030 (Million Units)
  • Figure 15.73 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, 2020-2030 (USD Million)
  • Figure 15.74 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, 2020-2030 (Million Units)
  • Figure 15.75 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, 2020-2030 (USD Million)
  • Figure 15.76 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.77 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.78 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.79 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.80 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.81 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.82 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.83 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.84 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.85 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.86 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.87 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.88 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.89 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.90 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.91 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.92 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.93 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.94 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, 2020-2030 (Million Units)
  • Figure 15.95 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, 2020-2030 (USD Million)
  • Figure 15.96 Prefilled Syringes Market for Infectious Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.97 Prefilled Syringes Market for Infectious Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.98 Prefilled Syringes Market for Infectious Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.99 Prefilled Syringes Market for Infectious Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.100 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.101 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.102 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.103 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.104 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.105 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.106 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.107 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.108 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.109 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.110 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.111 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.112 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.113 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.114 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, 2020-2030 (Million Units)
  • Figure 15.115 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, 2020-2030 (USD Million)
  • Figure 15.116 Prefilled Syringes Market for Neurological Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.117 Prefilled Syringes Market for Neurological Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.118 Prefilled Syringes Market for Neurological Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.119 Prefilled Syringes Market for Neurological Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.120 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.122 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.123 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.124 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.125 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.126 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.127 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.128 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.129 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.130 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.131 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.132 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.133 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.134 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.135 Prefilled Syringes Market for Blood Disorders: Share of Proteins, 2020-2030 (Million Units)
  • Figure 15.136 Prefilled Syringes Market for Blood Disorders: Share of Proteins, 2020-2030 (USD Million)
  • Figure 15.137 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, 2020-2030 (Million Units)
  • Figure 15.138 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, 2020-2030 (USD Million)
  • Figure 15.139 Prefilled Syringes Market for Blood Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.140 Prefilled Syringes Market for Blood Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.141 Prefilled Syringes Market for Blood Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.142 Prefilled Syringes Market for Blood Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.143 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.144 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.145 Prefilled Syringes Market for Blood Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.146 Prefilled Syringes Market for Blood Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.147 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.148 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.149 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.150 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.151 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.152 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.153 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.154 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.155 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.156 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.157 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, 2020-2030 (Million Units)
  • Figure 15.158 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, 2020-2030 (USD Million)
  • Figure 15.159 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, 2020-2030 (Million Units)
  • Figure 15.160 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, 2020-2030 (USD Million)
  • Figure 15.161 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, 2020-2030 (Million Units)
  • Figure 15.162 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, 2020-2030 (USD Million)
  • Figure 15.163 Prefilled Syringes Market for Oncological Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.164 Prefilled Syringes Market for Oncological Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.165 Prefilled Syringes Market for Oncological Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.166 Prefilled Syringes Market for Oncological Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.167 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.168 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.169 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.170 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.171 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.172 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.173 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.174 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.175 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.176 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.177 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.178 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.179 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.180 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.181 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, 2020-2030 (Million Units)
  • Figure 15.182 Prefilled Syringes Market for Metabolic Disorders: Share of Peptides, 2020-2030 (USD Million)
  • Figure 15.183 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.185 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.186Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.187 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.188 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.190 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.191 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.192 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.193 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.194 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 15.195 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.196 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.197 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.198 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.199 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.200 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.201 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
  • Figure 15.202 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
  • Figure 15.203 Prefilled Syringes Market for Other Disorders: Share of Antibodies, 2020-2030 (Million Units)
  • Figure 15.204 Prefilled Syringes Market for Other Disorders: Share of Antibodies, 2020-2030 (USD Million)
  • Figure 15.205 Prefilled Syringes Market for Other Disorders: Share of Peptide, 2020-2030 (Million Units)
  • Figure 15.206 Prefilled Syringes Market for Other Disorders: Share of Peptide, 2020-2030 (USD Million)
  • Figure 15.207 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, 2020-2030 (Million Units)
  • Figure 15.208 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, 2020-2030 (USD Million)
  • Figure 15.209 Prefilled Syringes Market for Other Disorders: Share of North America, 2020-2030 (Million Units)
  • Figure 15.210 Prefilled Syringes Market for Other Disorders: Share of North America, 2020-2030 (USD Million)
  • Figure 15.211 Prefilled Syringes Market for Other Disorders: Share of Europe, 2020-2030 (Million Units)
  • Figure 15.212 Prefilled Syringes Market for Other Disorders: Share of Europe, 2020-2030 (USD Million)
  • Figure 15.213 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
  • Figure 15.214 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
  • Figure 15.215 Prefilled Syringes Market for Other Disorders: Share of Latin America, 2020-2030 (Million Units)
  • Figure 15.216 Prefilled Syringes Market for Other Disorders: Share of Latin America, 2020-2030 (USD Million)
  • Figure 15.217 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
  • Figure 15.218 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
  • Figure 16.1 Diabetes: Country Wise Distribution of Prevalence and Mortality, 2017
  • Figure 16.2 FDA Approved Biologics, 2009-2019
  • Figure 16.3 Top Selling Biologics: Estimated Patent Expiry
  • Figure 17.1 SWOT Analysis
  • Figure 17.2Prefilled Syringe Recalls: Distribution by Type of Concern, 2003-2019
  • Figure 17.3 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 18.1 AptarGroup: Annual Revenues, 2013 - H1 2019 (USD Billion)
  • Figure 18.2 Datwyler Group: Annual Revenues, 2013 - H12019 (CHF Million)
  • Figure 18.3 Sumitomo Rubber Industries: Annual Revenues, 2013 - H1 2019 (JPY Billion)
  • Figure 18.4 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
  • Figure 19.1 Prefilled Syringe: Fill / Finish Process
  • Figure 19.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
  • Figure 19.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
  • Figure 19.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Geographical Location of Headquarters and Type of Drug Molecule
  • Figure 20.1 Elcam Medical: Product Portfolio
  • Figure 20.2 Elcam Medical: Flexi-Q Autoinjectors
  • Figure 20.3 Flexi-Q PFS: Components
  • Figure 20.4 Flexi-Q PFS: Mechanism of Drug Delivery
  • Figure 20.5 Flexi-Q DV: Components
  • Figure 20.6 Flexi-Q DV: Mechanism of Drug Delivery
  • Figure 20.7 Flexi-Q mMU: Components
  • Figure 20.8 Flexi-Q eMU: Components
  • Figure 20.9 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
  • Figure 20.10 Flexi-Q EAI: Mechanism of Drug Delivery
  • Figure 20.11 Owen Mumford: Product Portfolio
  • Figure 20.12 Autoject Micro: Mechanism of Drug Delivery
  • Figure 20.13 Autoject 2 Autoinjector: Mechanism of Drug Delivery
  • Figure 20.14 Autoject Mini: Mechanism of Drug Delivery
  • Figure 20.15 SHL Medical: Product Portfolio
  • Figure 20.16 SHL Medical: Prefilled Syringe-based Autoinjectors
  • Figure 20.17 SHL Medical: Cartridge-based Autoinjectors
  • Figure 20.18 SHL Medical: Two-Step Autoinjectors
  • Figure 20.19 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
  • Figure 20.20 Union Medico: 45° Autoinjector Portfolio
  • Figure 20.21 Union Medico: Parts of 45°/R Autoinjector
  • Figure 20.22 Union Medico: Types of 45°/R Autoinjector
  • Figure 20.23 Union Medico: Types of 90° Autoinjectors
  • Figure 20.24 Exclusive: Components
  • Figure 20.25 Ypsomed: Annual Revenues, FY 2014-15- FY 2018-19 (CHF Million)
  • Figure 20.26 Ypsomed: Sales by Business Divisions, FY 2018-19 (CHF Million, %)
  • Figure 20.27 Ypsomed: Product Portfolio
  • Figure 20.28 YpsoMate: Mechanism of Drug Delivery
  • Figure 20.29 VarioJect: Mechanism of Drug Delivery

List Of Tables

  • Table 3.1 Drugs: Shifted from Vials to Prefilled Syringe Systems
  • Table 3.2 Components of Prefilled Syringes
  • Table 3.3 Classification of Prefilled Syringes
  • Table 3.4 Advantages of Glass as Barrel Fabrication Material
  • Table 3.5 Glass Barrel Prefilled Syringe Recalls
  • Table 3.6 Advantages of Plastic Polymers as Barrel Fabrication Material
  • Table 3.7 Pharmaceutical Filling Lines: Steps Performed by Type of Packaging of Prefilled Syringe
  • Table 4.1 Prefilled Syringes: List of Available / Under Development Devices
  • Table 4.2 Prefilled Syringes: List of Developers
  • Table 6.1 Key Manufacturers of Prefilled Syringes
  • Table 6.2 Becton Dickinson: Future Outlook
  • Table 6.3 West Pharmaceutical: Features of Daikyo Crystal Zenith Prefilled Syringe
  • Table 6.4 West Pharmaceutical: Future Outlook
  • Table 6.5 Gerresheimer: Features of Gx Glass Prefilled Syringe
  • Table 6.6 Gerresheimer: Features of ClearJect Prefilled Syringe
  • Table 6.7 Gerresheimer: Future Outlook
  • Table 6.8 Ompi: Features of EZ-Fill Fina Prefilled Syringe
  • Table 6.9 Ompi: Features of EZ-Fill Nexa Prefilled Syringe
  • Table 6.10 Ompi: Features of EZ-Fill Alba Prefilled Syringe
  • Table 6.11 Ompi: Future Outlook
  • Table 6.12 SCHOTT: Features of syriQ Prefilled Syringe
  • Table 6.13 SCHOTT: Features of TopPac Prefilled Syringe
  • Table 6.14 SCHOTT: Future Outlook
  • Table 6.15 Nipro: Features of Prefilled Syringe
  • Table 6.16 Nipro: Future Outlook
  • Table 6.17 Weigao: Features of WeGo Glass Prefilled Syringe
  • Table 6.18 Taisei Kako: Features of VF-Syringes
  • Table 6.19 Taisei Kako: Features of SIN-Syringes
  • Table 6.20 Taisei Kako: Features of ClearJect Prefilled Syringes
  • Table 6.21 Taisei Kako: Features of FULJECT Passive Type Syringes
  • Table 6.22 Terumo: Future Outlook
  • Table 6.23 Shandong Zibo: Features of Prefilled Syringes
  • Table 6.24Vetter Pharma: Features of Lyo-Ject Glass Prefilled Syringe
  • Table 7.1 Add-On Safety Device Manufacturers
  • Table 7.2 Integrated Prefilled Safety Device Manufacturers
  • Table 8.1 US FDA Center for Drug and Device Approval
  • Table 8.2 Regulatory Review Timelines in the US
  • Table 8.3 Regulatory Bodies in EU5 Countries
  • Table 8.4 Device Classification: Japan
  • Table 8.5 Regulatory Review Timelines in Saudi Arabia
  • Table 9.1 Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
  • Table 9.2 Prefilled Syringe Combination Products: Information on Approval Years and Geographies, 2013-2019
  • Table 9.3 Prefilled Syringe Combination Products: Information on Dosage Strength
  • Table 9.4 Prefilled Syringe Combination Products: List of Other Drug Delivery Solutions, 2013-2019
  • Table 9.5 Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2019
  • Table 9.6 Prefilled Syringe Combination Products: List of Developers
  • Table 9.7 Other Drugs Sold in Prefilled Syringes
  • Table 10.1 Autoimmune Disorders: Leading Approved Drugs
  • Table 10.2 Autoimmune Disorders: Approved Drugs Available in Prefilled Syringes
  • Table 10.3 Autoimmune Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development
  • Table 10.4 Infectious Diseases: Leading Antiviral Drugs
  • Table 10.5 Infectious Diseases: Antiviral Drugs Available in Prefilled Syringes
  • Table 10.6 Infectious Diseases: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development
  • Table 10.7 Infectious Diseases: Leading Vaccines
  • Table 10.8 Infectious Diseases: Vaccines Available in Prefilled Syringes
  • Table 10.9 Neurological Disorders: Leading Drugs
  • Table 10.10 Neurological Disorders: Approved Drugs Available in Prefilled Syringes
  • Table 10.11 Neurological Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development
  • Table 10.12 Metabolic Disorders: Leading Diabetes Drugs
  • Table 10.13 Metabolic Disorders: Approved Drugs Available in Prefilled Insulin Pen
  • Table 10.14 Metabolic Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development
  • Table 11.1 Marketed Drugs: Most Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.2 Marketed Drugs: Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.3 Marketed Drugs: Less Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.4 Marketed Drugs: Least Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.5 Clinical Stage Drug Candidates: Most Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.6 Clinical Stage Drug Candidates: Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.7 Clinical Stage Drug Candidates: Less Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.8 Clinical Stage Drug Candidates: Least Likely Candidates for Delivery via Prefilled Syringes
  • Table 11.9 Opportunities in North America: Most Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.10 Opportunities in North America: Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.11 Opportunities in North America: Less Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.12 Opportunities in North America: Least Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.13 Opportunities in Europe: Most Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.14 Opportunities in Europe: Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.15 Opportunities in Europe: Less Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.16 Opportunities in Europe: Least Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.17 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners Prefilled Syringe Combination Product Development
  • Table 11.18 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Prefilled Syringe Combination Product Development
  • Table 11.19 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners Prefilled Syringe Combination Product Development
  • Table 11.20 Opportunities in Asia-Pacific and Rest of the World: Least Likely Partners Prefilled Syringe Combination Product Development
  • Table 13.1 Prefilled Flush Syringes Available in the Market
  • Table 13.2 Drugs Available with Prefilled Diluent Syringe Systems
  • Table 13.3 Contrast Agents Available in Prefilled Syringes
  • Table 14.1Dual / Multi-Chamber Prefilled Syringes
  • Table 14.2Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
  • Table 15.1Therapeutic Areas: Relative Share of Approved and Clinical Products with Prefilled Syringes
  • Table 16.1 Fraction of Global Population above 60 years (in Millions), 2017, 2030 and 2050
  • Table 16.2 Autoinjector Approvals, 2016-2019
  • Table 16.3 Marketed Autoinjectors / Pen Injectors with Prefilled Syringes
  • Table 17.1 List of Marketed/Pipeline Needleless Injection Devices
  • Table 17.2 Prefilled Syringe Recalls, 2003-2019
  • Table 18.1 Prefilled Syringe Component Manufacturers: List of Elastomeric Component Providers
  • Table 18.2 Prefilled Syringes Elastomeric Container Closure Providers: List of Companies Profiled
  • Table 18.3 AptarGroup: Company Overview
  • Table 18.4 Aptar Pharma: Product Details
  • Table 18.5 AptarGroup: Recent Developments and Future Outlook
  • Table 18.6 West Pharmaceutical: Company Overview
  • Table 18.7 West Pharmaceutical: Product Details
  • Table 18.8 Datwyler Sealing Solutions (Datwyler Group): Company Overview
  • Table 18.9 Datwyler Sealing Solutions (Datwyler Group): Product Details
  • Table 18.10 Datwyler Sealing Solutions (Datwyler Group): Recent Developments and Future Outlook
  • Table 18.11 Lonstroff: Company Overview
  • Table 18.12 Sumitomo Rubber Industries: Company Overview
  • Table 18.13 Lonstroff: Product Details
  • Table 18.14 Sumitomo Rubber Industries: Recent Developments and Future Outlook
  • Table 18.15 Ompi (Stevanato Group): Company Overview
  • Table 18.16 Ompi (Stevanato Group): Product Details
  • Table 18.17 Jiangsu Hualan Pharmaceutical New Material: Company Overview
  • Table 18.18 Jiangsu Hualan Pharmaceutical New Material: Product Details
  • Table 19.1 List of Fill / Finish Service Providers
  • Table 20.1 List of Autoinjector Devices (Using Prefilled Syringes)
  • Table 20.2 YpsoMate Autoinjectors: Dimensions of Prefilled Syringes
  • Table 21.1 Prefilled Syringes Market: Key Takeaways
  • Table 22.1 Oval Medical Technologies: Key Highlights
  • Table 22.2 Intas Pharmaceuticals: Key Highlights
  • Table 22.3 IDT Biologika: Key Highlights
  • Table 22.4 West Pharmaceutical: Key Highlights
  • Table 22.5 Lonstroff: Key Highlights
  • Table 23.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
  • Table 23.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Table 23.3 Prefilled Syringes: Distribution by Type of Needle System
  • Table 23.4 Prefilled Syringes: Distribution by Device Capacity
  • Table 23.5 Prefilled Syringe Developers: Distribution by Year of Establishment
  • Table 23.6 Prefilled Syringe Developers: Distribution by Company Size
  • Table 23.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
  • Table 23.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
  • Table 23.9 BD Medical: Annual Revenues, FY 2011 - FY 2018 (USD Billion)
  • Table 23.10 BD Medical: Revenue Distribution by Sub-Segments, FY 2018 (USD Billion)
  • Table 23.11 West Pharmaceutical: Annual Revenues, 2011-H1 2019 (USD Million)
  • Table 23.12 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
  • Table 23.13 West Pharmaceutical: Revenue Distribution by Region 2018 (USD Million)
  • Table 23.14 Gerresheimer: Annual Revenues, 2011-H1 2019 (EUR Million)
  • Table 23.15 Gerresheimer: Revenue Distribution by Business Divisions, FY 2018 (EUR Million)
  • Table 23.16 Gerresheimer: Revenue Distribution by Region, FY 2018 (EUR Million)
  • Table 23.17 Schott: Annual Revenues, FY 2013-FY 2018 (EUR Million)
  • Table 23.18 Schott: Revenue Distribution by Geography, FY 2018 (EUR Million)
  • Table 23.19 Nipro: Annual Revenues, FY 2012 - FY 2019 (JPY Billion)
  • Table 23.20 Nipro: Revenue Distribution by Business Divisions, FY 2019(JPY Billion)
  • Table 23.21 Nipro: Revenue Distribution by Region, FY 2019 (JPY Billion)
  • Table 23.22 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
  • Table 23.23 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
  • Table 23.24 Terumo: Annual Revenues, FY 2012 - FY 2019 (JPY Billion)
  • Table 23.25 Terumo: Revenue Distribution by Business Divisions, FY 2018 (JPY Billion)
  • Table 23.26 Terumo: Revenue Distribution by Region, FY 2018 (JPY Billion)
  • Table 23.27 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
  • Table 23.28 Approved Prefilled Syringe Combination Products: Distribution by Approval Year
  • Table 23.29 Approved Prefilled Syringe Combination Products: Distribution by Approval Geographies
  • Table 23.30 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
  • Table 23.31 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
  • Table 23.32 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
  • Table 23.33 Pipeline Prefilled Syringes Combination Products: Distribution by Type of Drug
  • Table 23.34 Pipeline Prefilled Syringes Combination Products: Distribution by Phase of Development
  • Table 23.35 Pipeline Prefilled Syringes Combination Products: Distribution by Route of Administration
  • Table 23.36 Pipeline Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
  • Table 23.37 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
  • Table 23.38 Prefilled Syringe Combination Product Developers: Distribution by Company Size
  • Table 23.39 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
  • Table 23.40 HUMIRA®: Annual Sales, 2003-H1 2019 (USD Million)
  • Table 23.41 Enbrel®: Annual Sales in the US and Canada, 2002-H1 2019 (USD Million)
  • Table 23.42 Enbrel®: Annual Sales Outside the US and Canada, 2002-H1 2019 (USD Million)
  • Table 23.43 Prefilled Syringe Prices, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
  • Table 23.44 Global Prefilled Syringes Market, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.45 Global Prefilled Syringes Market, Base Scenario, 2020-2030 (Million Units)
  • Table 23.46 Global Prefilled Syringes Market, Optimistic Scenario, 2019-2030 (Million Units)
  • Table 23.47 Global Prefilled Syringes Market, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.48 Global Prefilled Syringes Market, Base Scenario, 2020-2030 (USD Million)
  • Table 23.49 Global Prefilled Syringes Market, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.50 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.51 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.52 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.53 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.54 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.55 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.56 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.57 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2020-2030 (Million Units)
  • Table 23.58 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.59 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.60 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2020-2030 (USD Million)
  • Table 23.61 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.62 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.63 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.64 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.65 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.66 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.67 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.68 Prefilled Syringes Market: Share of Blood Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.69 Prefilled Syringes Market: Share of Blood Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.70 Prefilled Syringes Market: Share of Blood Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.71 Prefilled Syringes Market: Share of Blood Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.72 Prefilled Syringes Market: Share of Blood Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.73 Prefilled Syringes Market: Share of Blood Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.74 Prefilled Syringes Market: Share of Oncological Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.75 Prefilled Syringes Market: Share of Oncological Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.76 Prefilled Syringes Market: Share of Oncological Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.77 Prefilled Syringes Market: Share of Oncological Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.78 Prefilled Syringes Market: Share of Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.79 Prefilled Syringes Market: Share of Oncological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.80 Prefilled Syringes Market: Share of Psychiatric Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.81 Prefilled Syringes Market: Share of Psychiatric Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.82 Prefilled Syringes Market: Share of Psychiatric Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.83 Prefilled Syringes Market: Share of Psychiatric Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.84 Prefilled Syringes Market: Share of Psychiatric Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.85 Prefilled Syringes Market: Share of Psychiatric Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.86 Prefilled Syringes Market: Share of Respiratory Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.87 Prefilled Syringes Market: Share of Respiratory Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.88 Prefilled Syringes Market: Share of Respiratory Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.89 Prefilled Syringes Market: Share of Respiratory Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.90 Prefilled Syringes Market: Share of Respiratory Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.91 Prefilled Syringes Market: Share of Respiratory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.92 Prefilled Syringes Market: Share of Cardiovascular Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.93 Prefilled Syringes Market: Share of Cardiovascular Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.94 Prefilled Syringes Market: Share of Cardiovascular Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.95 Prefilled Syringes Market: Share of Cardiovascular Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.96 Prefilled Syringes Market: Share of Cardiovascular Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.97 Prefilled Syringes Market: Share of Cardiovascular Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.98 Prefilled Syringes Market: Share of Metabolic Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.99 Prefilled Syringes Market: Share of Metabolic Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.100 Prefilled Syringes Market: Share of Metabolic Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.101 Prefilled Syringes Market: Share of Metabolic Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.102 Prefilled Syringes Market: Share of Metabolic Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.103 Prefilled Syringes Market: Share of Metabolic Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.104 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.105 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2020-2030 (Million Units)
  • Table 23.106 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.107 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.108 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2020-2030 (USD Million)
  • Table 23.109 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.110 Prefilled Syringes Market: Share of Orthopedic Disorders, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.111 Prefilled Syringes Market: Share of Orthopedic Disorders, Base Scenario, 2020-2030 (Million Units)
  • Table 23.112 Prefilled Syringes Market: Share of Orthopedic Disorders, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.113 Prefilled Syringes Market: Share of Orthopedic Disorders, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.114 Prefilled Syringes Market: Share of Orthopedic Disorders, Base Scenario, 2020-2030 (USD Million)
  • Table 23.115 Prefilled Syringes Market: Share of Orthopedic Disorders, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.116 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.117 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2020-2030 (Million Units)
  • Table 23.118 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.119 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.120 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2020-2030 (USD Million)
  • Table 23.121 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.122 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.123 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Base Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.124 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.125 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.126 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.127 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.128 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.129 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.130 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.131 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.132 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.133 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.134 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.135 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.136 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.137 Prefilled Syringes Market: Distribution by Type of Chamber System, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.138 Prefilled Syringes Market: Distribution by Type of Chamber System, Base Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.139 Prefilled Syringes Market: Distribution by Type of Chamber System, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.140 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.141 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.142 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.143 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.144 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.145 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.146 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.147 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.148 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.149 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.150 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.151 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.152 Prefilled Syringes Market: Distribution by Therapeutic Area, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.153 Prefilled Syringes Market: Distribution by Therapeutic Area, Base Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.154 Prefilled Syringes Market: Distribution by Therapeutic Area, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
  • Table 23.155 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.156 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
  • Table 23.157 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.158 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.159 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
  • Table 23.160 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.161 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.162 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
  • Table 23.163 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.164 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.165 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
  • Table 23.166 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.167 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.168 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2020-2030 (Million Units)
  • Table 23.169 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.170 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.171 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2020-2030 (USD Million)
  • Table 23.172 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.173 Global Prefilled Syringes Market: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.174 Global Prefilled Syringes Market: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
  • Table 23.175 Global Prefilled Syringes Market: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.176 Global Prefilled Syringes Market: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.177 Global Prefilled Syringes Market: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
  • Table 23.178 Global Prefilled Syringes Market: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.179 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.180 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2020-2030 (Million Units)
  • Table 23.181 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.182 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.183 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2020-2030 (USD Million)
  • Table 23.184 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.185 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.186 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.187 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.188 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.189 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.190 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.191 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.192 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.193 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.194 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.195 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.196 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.197 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.198 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.199 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.200 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.201 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.202 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.203 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.204 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.205 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.206 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.207 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.208 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.209 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.210 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.211 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.212 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.213 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.214 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.215 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.216 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.217 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.218 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.219 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.220 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.221 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.222 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.223 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.224 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.225 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.226 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.227 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.228 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.229 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.230 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.231 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.232 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.233 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.234 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.235 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.236 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.237 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.238 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.239 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.240 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.241 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.242 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.243 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.244 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.245 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.246 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
  • Table 23.247 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.248 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.249 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
  • Table 23.250 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.251 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.252 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
  • Table 23.253 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.254 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.255 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
  • Table 23.256 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.257 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.258 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.259 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.260 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.261 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.262 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.263 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.264 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.265 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.166 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.267 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.268 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.269 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.270 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.271 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.272 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.273 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.274 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.275 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.276 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.277 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.279 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.280 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.281 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.282 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.283 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.284 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.285 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.286 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.287 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.288 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.289 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.290 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.291 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.292 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.293 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.294 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.295 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.296 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.297 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.298 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.299 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.300 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.301 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.302 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.303 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.304 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.305 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.306 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.307 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.308 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.309 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.310 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.311 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.312 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.313 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Base Scenario, 2020-2030 (Million Units)
  • Table 23.314 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.315 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.316 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Base Scenario, 2020-2030 (USD Million)
  • Table 23.317 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.318 Prefilled Syringes Market for Infectious Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.319 Prefilled Syringes Market for Infectious Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.320 Prefilled Syringes Market for Infectious Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.321 Prefilled Syringes Market for Infectious Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.322 Prefilled Syringes Market for Infectious Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.323 Prefilled Syringes Market for Infectious Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.324 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.325 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.326 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.327 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.328 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.329 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.330 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.331 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.332 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.333 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.334 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.335 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.336 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.337 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.338 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.339 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.340 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.341 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.342 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.343 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.344 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.345 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.346 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.347 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.348 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.349 Prefilled Syringes Market for Neurological e Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.350 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.351 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.352 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.353 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.354 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.355 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.356 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.357 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.358 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.359 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.360 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.361 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.362 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.363 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.365 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.366 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.367 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.368 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.369 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 370 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.371 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.372 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.373 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.374 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
  • Table 23.375 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.376 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.377 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
  • Table 23.378 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.379 Prefilled Syringes Market for Neurological Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.380 Prefilled Syringes Market for Neurological Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.381 Prefilled Syringes Market for Neurological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.382 Prefilled Syringes Market for Neurological Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.383 Prefilled Syringes Market for Neurological Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.384 Prefilled Syringes Market for Neurological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.385 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.386 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.387 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.388 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.389 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.390 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.391 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.392 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.393 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.394 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.395 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.396 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.399 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.400 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.401 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.402 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.403 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.404 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.405 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.406 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.407 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.408 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.409 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.410 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.411 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.412 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.413 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.414 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.415 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.416 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.417 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.418 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.419 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.420 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.421 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.422 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.423 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.424 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.425 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.426 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.427 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.428 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.429 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.430 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.431 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.432 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.433 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.434 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.435 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.436 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
  • Table 23.437 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.438 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.439 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
  • Table 23.440 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.441 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.442 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
  • Table 23.443 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.444 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.445 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
  • Table 23.446 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.447 Prefilled Syringes Market for Blood Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.448 Prefilled Syringes Market for Blood Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.449 Prefilled Syringes Market for Blood Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.450 Prefilled Syringes Market for Blood Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.451 Prefilled Syringes Market for Blood Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.452 Prefilled Syringes Market for Blood Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.453 Prefilled Syringes Market for Blood Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.454 Prefilled Syringes Market for Blood Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.455 Prefilled Syringes Market for Blood Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.456 Prefilled Syringes Market for Blood Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.457 Prefilled Syringes Market for Blood Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.458 Prefilled Syringes Market for Blood Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.459 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.460 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.461 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.462 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.463 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.464 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.465 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.466 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.469 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.470 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.471 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.472 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.473 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.474 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.475 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.476 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.477 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.478 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.479 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.480 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.481 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.482 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.483 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.484 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.485 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.486 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.487 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.488 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.489 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.490 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.491 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.492 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.493 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.494 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.496 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.497 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.498 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.499 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.500 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.501 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.502 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.503 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.504 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.505 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
  • Table 23.506 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.507 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.508 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
  • Table 23.509 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.510 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.511 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
  • Table 23.512 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.513 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.514 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
  • Table 23.515 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.516 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.517 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
  • Table 23.518 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.519 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.520 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
  • Table 23.521 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.522 Prefilled Syringes Market for Oncological Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.523 Prefilled Syringes Market for Oncological Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.524 Prefilled Syringes Market for Oncological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.525 Prefilled Syringes Market for Oncological Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.526 Prefilled Syringes Market for Oncological Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.527 Prefilled Syringes Market for Oncological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.528 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.529 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.530 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.531 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.532 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.533 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.534 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.535 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.536 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.537 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.538 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.539 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.540 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.541 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.542 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.543 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.544 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.545 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.546 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.547 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.548 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.549 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.550 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.551 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.552 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.553 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.554 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.555 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.556 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.557 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.558 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.559 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.560 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.561 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.562 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.563 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.564 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.565 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.566 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.567 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.568 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.569 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.570 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.571 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.572 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.573 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.573 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.575 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.576 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.577 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
  • Table 23.578 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.579 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.580 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
  • Table 23.581 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.582 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.583 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.584 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.585 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.586 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.587 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.588 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.589 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.590 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.591 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.592 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.593 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.594 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.595 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.596 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.597 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.598 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.599 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.600 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.601 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.602 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.603 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.604 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.605 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.606 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.607 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.608 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.609 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.610 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.612 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.613 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.614 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.615 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.616 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.617 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.618 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.619 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
  • Table 23.620 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.621 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.622 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.623 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.624 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.625 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.626 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.627 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.628 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.629 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.630 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.631 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.632 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
  • Table 23.633 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.634 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.635 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
  • Table 23.636 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.637 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.638 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
  • Table 23.639 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.640 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.641 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
  • Table 23.642 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.643 Prefilled Syringes Market for Other Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.644 Prefilled Syringes Market for Other Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
  • Table 23.645 Prefilled Syringes Market for Other Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.646 Prefilled Syringes Market for Other Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.647 Prefilled Syringes Market for Other Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
  • Table 23.648 Prefilled Syringes Market for Other Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.649 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.650 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
  • Table 23.651 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.652 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.653 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
  • Table 23.654 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.655 Prefilled Syringes Market for Other Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.656 Prefilled Syringes Market for Other Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.657 Prefilled Syringes Market for Other Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.658 Prefilled Syringes Market for Other Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.659 Prefilled Syringes Market for Other Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.660 Prefilled Syringes Market for Other Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.661 Prefilled Syringes Market for Other Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.662 Prefilled Syringes Market for Other Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
  • Table 23.663 Prefilled Syringes Market for Other Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.664 Prefilled Syringes Market for Other Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.665 Prefilled Syringes Market for Other Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
  • Table 23.666 Prefilled Syringes Market for Other Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.667 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.668 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
  • Table 23.669 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.670 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.671 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
  • Table 23.672 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.673 Prefilled Syringes Market for Other Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.674 Prefilled Syringes Market for Other Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
  • Table 23.675 Prefilled Syringes Market for Other Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.676 Prefilled Syringes Market for Other Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.677 Prefilled Syringes Market for Other Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
  • Table 23.678 Prefilled Syringes Market for Other Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.679 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
  • Table 23.680 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
  • Table 23.681 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
  • Table 23.682 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
  • Table 23.683 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
  • Table 23.684 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
  • Table 23.685 Sales of Leading Drugs Available in Prefilled Syringes, 2018 (USD Billion)
  • Table 23.686 FDA Approved Biologics, 2009-2019
  • Table 23.689 Aptar Group: Annual Revenues, 2013-H1 2019 (USD Billion)
  • Table 23.690 Datwyler Group: Annual Revenues, 2013-H1 2019 (CHF Million)
  • Table 23.691 Sumitomo Rubber Industries: Annual Revenues, 2013-H1 2019 (JPY Billion)
  • Table 23.692 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
  • Table 23.693 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
  • Table 23.694 Prefilled Syringes Fill / Finish Service Providers: Distribution by Scale of Operation

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3D Medicines
  • 2. Abbott
  • 3. AbbVie
  • 4. Abivax
  • 5. Ablynx
  • 6. Acceleron Pharma
  • 7. Accord Healthcare
  • 8. Activa Brand Products
  • 9. Adamis Pharmaceuticals
  • 10. Adimmune
  • 11. Adocia
  • 12. Advance Pharma Lab
  • 13. Aerpio Therapeutics
  • 14. Affibody
  • 15. Agenus
  • 16. Aguettant
  • 17. Aijex Pharma International
  • 18. Ajinomoto Bio-Pharma Services
  • 19. Akeso Biopharma
  • 20. AKRA DERMOJET
  • 21. Akums Drugs & Pharmaceuticals
  • 22. Al Biosciences
  • 23. Alder BioPharmaceuticals
  • 24. Alexion
  • 25. Alfa Corpuscles
  • 26. Alfasigma
  • 27. Alkermes
  • 28. Allergan
  • 29. Alnylam Pharmaceuticals
  • 30. Alphamab Jilin
  • 31. Altor BioScience
  • 32. Alvogen
  • 33. Alvotech
  • 34. Alzheimer's Association
  • 35. AMAG Pharmaceuticals
  • 36. Amega Biotech
  • 37. Amgen
  • 38. AMRI
  • 39. AnaptysBio
  • 40. Andes Biotechnologies
  • 41. Antares Pharma
  • 42. Antev
  • 43. Apellis Pharmaceuticals
  • 44. APL (Apotek Produktion & Laboratorier)
  • 45. Apobiologix
  • 46. Aptar Pharma
  • 47. Aquabiliti
  • 48. Araclon Biotech
  • 49. Archivel Farma
  • 50. Arecor
  • 51. Arrowhead Pharmaceuticals
  • 52. Arte
  • 53. Asarina Pharma
  • 54. Ascendis Pharma
  • 55. ASIT biotech
  • 56. Assistance Publique Hôpitaux de Paris
  • 57. Astellas Pharma
  • 58. AstraZeneca
  • 59. AV7
  • 60. Axon Neuroscience
  • 61. B. Braun Medical
  • 62. Bavarian Nordic
  • 63. Baxalta
  • 64. Baxter
  • 65. Bayer
  • 66. Becton Dickinson
  • 67. Bespak
  • 68. Beximco Pharma
  • 69. Biocad
  • 70. Biocon
  • 71. Biocorp
  • 72. Biogen
  • 73. BioGenCell
  • 74. Bioinova
  • 75. BioLineRx
  • 76. BioMarin Pharmaceutical
  • 77. BioMimetix
  • 78. BioPharma Solutions (a business unit of Baxter)
  • 79. BioValve Technologies
  • 80. BirgiMefar
  • 81. Boehringer Ingelheim
  • 82. Bone Therapeutics
  • 83. Boryung Pharmaceutical
  • 84. Boston Biomedical
  • 85. Boston Pharmaceuticals
  • 86. Bracco Diagnostics
  • 87. Braeburn Pharmaceuticals
  • 88. Bristol-Myers Squibb
  • 89. Brooklyn ImmunoTherapeutics
  • 90. Caladrius Biosciences
  • 91. Camurus
  • 92. CARBOGEN AMCIS
  • 93. Cardinal Health
  • 94. Catalent
  • 95. Catalyst Biosciences
  • 96. CeleCor Therapeutics
  • 97. Celgene
  • 98. Celldex Therapeutics
  • 99. Celltrion
  • 100. Cenexi
  • 101. Centrexion Therapeutics
  • 102. CinnaGen
  • 103. Ciron Drugs
  • 104. Civi Biopharma
  • 105. Coherus Biosciences
  • 106. Consort Medical
  • 107. Corden Pharma
  • 108. Corvidia Therapeutics
  • 109. Covidien
  • 110. Credence Medsystems
  • 111. CrossJect
  • 112. CSL Behring
  • 113. CSPC ZhongQi Pharmaceutical Technology
  • 114. CytoDyn
  • 115. Daewoong Pharmaceutical
  • 116. Daiichi Sankyo
  • 117. DALI Medical Devices
  • 118. Datwlyer
  • 119. Delpharm
  • 120. DiaMedica Therapeutics
  • 121. Dicerna Pharmaceuticals
  • 122. Dr. Reddy's Laboratory
  • 123. Dynavax Technologies
  • 124. E3D
  • 125. Eisai
  • 126. Elcam Medical
  • 127. Eli Lilly
  • 128. Eloxx Pharmaceuticals
  • 129. Emcure Pharmaceuticals
  • 130. EMD Serono
  • 131. Emergent BioSolutions
  • 132. Enzon Pharma
  • 133. Ever Pharma
  • 134. Excelsior Medical
  • 135. Ferring Pharmaceuticals
  • 136. Follicum
  • 137. Foresee Pharmaceutical
  • 138. Fresenius Kabi
  • 139. Fujifilm Kyowa Kirin Biologics
  • 140. Future Injection Technologies
  • 141. Galapagos
  • 142. GC Pharma
  • 143. GE Healthcare
  • 144. Genentech
  • 145. Generon (Shanghai)
  • 146. Genexine
  • 147. Genocea Biosciences
  • 148. Genzyme
  • 149. GERCOR
  • 150. Gerresheimer
  • 151. Getz Pharma
  • 152. Gland Pharma
  • 153. GSK
  • 154. Guerbet
  • 155. HAL Allergy
  • 156. Hanmi Pharmaceutical
  • 157. Harbour BioMed
  • 158. Haselmeier
  • 159. Healthcare Pharmaceuticals
  • 160. Helixmith
  • 161. Hengrui Yuanzheng Bio-Technology
  • 162. Heron Therapeutics
  • 163. Hetero Drugs
  • 164. Hexal
  • 165. IDT Biologika
  • 166. Iltoo Pharma
  • 167. Il-Yang Pharmaceutical
  • 168. Immune Response BioPharma
  • 169. ImmunoVaccine
  • 170. Immunovant Sciences
  • 171. Immutep Australia
  • 172. Injecto
  • 173. Injex
  • 174. Inmune Bio
  • 175. Innovent Biologics
  • 176. Inovio Pharmaceuticals
  • 177. Intas Pharmaceuticals
  • 178. Intron Biotechnology
  • 179. Ionis Pharmaceuticals
  • 180. Ipsen
  • 181. ISU Abxis
  • 182. Italfarmaco
  • 183. Izana Bioscience
  • 184. J.O. Pharma
  • 185. Janssen
  • 186. Jiangsu Hansoh Pharmaceutical
  • 187. Jiangsu HengRui Medicine
  • 188. Jiangsu Hualan Pharmaceutical New Material
  • 189. Jiangsu T-Mab Biopharma
  • 190. Jiangxi Sanxin Medtec
  • 191. Jinan Youlyy Industrial
  • 192. Johnson & Johnson
  • 193. Kaleo Pharma
  • 194. Kang Stem Biotech
  • 195. Kemwell Biopharma
  • 196. KeyBioscience
  • 197. Kezar Life Sciences
  • 198. Kiniksa Pharmaceuticals
  • 199. Kyowa Hakko Kirin
  • 200. La Jolla Pharmaceutical
  • 201. Laboratorios SALVAT
  • 202. LEO Pharma
  • 203. LG Chem
  • 204. LIB Therapeutics
  • 205. Lonstroff
  • 206. Lonza
  • 207. Lundbeck
  • 208. Luye Pharma
  • 209. M3 Biotechnology
  • 210. Mada Medical Products
  • 211. Mallinckrodt
  • 212. Medefil
  • 213. Medicago
  • 214. MedicalChain International
  • 215. Medigen Vaccine Biologics
  • 216. MedImmune
  • 217. MedPro Safety Products
  • 218. Medtronic
  • 219. MedxL
  • 220. Merck
  • 221. Merck Serono
  • 222. Meridian
  • 223. Merit Medical
  • 224. Mika Medical
  • 225. Millendo Therapeutics
  • 226. Millennium Pharmaceuticals
  • 227. Minervax
  • 228. miRagen Therapeutics
  • 229. Mithra Pharmaceuticals
  • 230. Mitsubishi Tanabe
  • 231. Modus Therapeutics
  • 232. Mologen
  • 233. Mylan
  • 234. Nektar Therapeutics
  • 235. Nemera
  • 236. NeoImmuneTech
  • 237. Neumedicines
  • 238. Neuraly
  • 239. NGM Biopharmaceuticals
  • 240. Ningbo Zhengli Pharmaceutical Packing
  • 241. NIPRO
  • 242. Nora Therapeutics
  • 243. Nordic Bioscience
  • 244. NovaDigm Therapeutics
  • 245. Novartis
  • 246. Novavax
  • 247. Novo Nordisk
  • 248. NPS Pharmaceuticals (a subsidiary of Shire)
  • 249. Nuance Designs
  • 250. Nurse Assist
  • 251. OBI Pharma
  • 252. OliPass
  • 253. Olix Pharmaceuticals
  • 254. Ology Bioservices
  • 255. Omeros
  • 256. Ompi
  • 257. Oncobiologics
  • 258. Oncolix
  • 259. OncoPep
  • 260. OncoTherapy Science
  • 261. Oncovir
  • 262. OPKO Health
  • 263. Optimum Medical
  • 264. Orphan Disease Treatment Institute
  • 265. Osivax
  • 266. Otsuka Pharmaceutical
  • 267. Oval Medical Technologies
  • 268. Owen Mumford
  • 269. PA Consulting
  • 270. Palatin Technologies
  • 271. Patheon
  • 272. PCI Pharma Services
  • 273. PegBio
  • 274. PenJet
  • 275. Pfizer
  • 276. Pfizer CentreOne
  • 277. PharmaJet
  • 278. PhaseBio Pharmaceuticals
  • 279. PHC Injection Device Technologies
  • 280. Piramal Enterprises
  • 281. Pisa Farmaceutica
  • 282. Plas-Tech Engineering
  • 283. Pluristem Therapeutics
  • 284. Polaris Group
  • 285. PRA Health Sciences
  • 286. Primequal
  • 287. ProJect Pharmaceutics
  • 288. Promius Pharma
  • 289. Protagonist Therapeutics
  • 290. Proteo Biotech
  • 291. Qilu Pharmaceutical
  • 292. Qu Biologics
  • 293. Quratis
  • 294. Ra Pharmaceuticals
  • 295. Rafa Laboratories
  • 296. Raumedic
  • 297. Regenera Pharma
  • 298. Regeneron
  • 299. Reliance Life Sciences
  • 300. REMD Biotherapeutics
  • 301. Rentschler Biopharma
  • 302. Retractable Technologies
  • 303. Revolutions Medical
  • 304. RHEACELL
  • 305. Rhythm Pharmaceuticals
  • 306. Roche
  • 307. Roselabs biosciences
  • 308. Rovi Pharmaceutical
  • 309. R-Pharm
  • 310. Samsung Bioepis
  • 311. Samsung Biologics
  • 312. Sandoz
  • 313. Sanofi
  • 314. SCHERDEL Medtec
  • 315. Schering Medipharm
  • 316. Schott
  • 317. Schott-Kaisha
  • 318. Seqirus
  • 319. Serina Therapeutics
  • 320. Shandong Pharmaceutical Glass
  • 321. Shandong Weigao
  • 322. Shandong Zibo Minkang Pharmaceutical Packing
  • 323. Shanghai Biomabs Pharmaceutical
  • 324. Shenyang Sunshine Pharmaceutical
  • 325. Shin Yan Sheno Precision Industrial
  • 326. Shire
  • 327. SHL Group
  • 328. Siegfried Holding
  • 329. Sinocelltech
  • 330. SiO2 Medical Products
  • 331. Smiths Medical
  • 332. Swedish Orphan Biovitrum (SOBI)
  • 333. Spectrum Pharmaceuticals
  • 334. Splash Pharmaceuticals
  • 335. Square Pharmaceuticals
  • 336. SRI International
  • 337. Stealth BioTherapeutics
  • 338. Sun BioPharma
  • 339. Sun Pharma
  • 340. Suzuken
  • 341. SynDevRx
  • 342. Synermore Biologics
  • 343. Taisei Kako
  • 344. Takeda
  • 345. Terumo Europe
  • 346. Teva Pharmaceutical
  • 347. The Medical House
  • 348. The Medicines Company
  • 349. The National Medical Products
  • 350. Themis Bioscience
  • 351. Therachon
  • 352. TikoMed
  • 353. Tip-Top
  • 354. Tolmar
  • 355. Transcoject
  • 356. Transgene
  • 357. Troikaa
  • 358. Turnstone Biologics
  • 359. Tyfill Pharmapack
  • 360. UCB Biopharma
  • 361. Union Medico
  • 362. United Neuroscience
  • 363. US Medical Instruments
  • 364. Vaccibody
  • 365. Vaccitech
  • 366. Valeant Pharmaceutical
  • 367. Valeritas
  • 368. Valneva
  • 369. Vaxine
  • 370. Vetter Pharma
  • 371. Viela Bio
  • 372. ViiV Healthcare
  • 373. Vir Biotechnology
  • 374. Viriom
  • 375. Vitaeris
  • 376. VLP Therapeutics
  • 377. West Pharmaceutical
  • 378. Xbiotech
  • 379. XEME Biopharma
  • 380. YangZhong Wealth Metal
  • 381. YL Biologics
  • 382. Ypsomed
  • 383. Zealand Pharma
  • 384. Zhejiang Huahai Pharmaceutical
  • 385. Zogenix
  • 386. ZymoGenetics
目次

Example Insights:

Case Study: The market is also characterized by the presence of many contract service providers, spread across the world, offering fill / finish services in prefilled syringes.

Overview:

"We are seeing an increased demand in the emerging markets, particularly within the BRICS nations, namely Brazil, Russia, India, China and South Africa. North Africa and the Middle East also present a similar scenario, characterized by a growth rate of 10-18% for prefilled syringes." - Marketing Director, a large-sized company.

According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases. Chronic clinical conditions are considered to be among the leading causes of death and disability across the world. Typically, in such cases, individuals are required to medicate on a daily basis. In addition to the cost of medication, such individuals are also burdened with a deteriorating quality of life, and often struggle with medication adherence. According to the US Centers for Disease Control (CDC), the overall annual expense incurred by those living with chronic diseases is steadily growing and is currently estimated to be more than USD 3 trillion. The development and commercialization of self-administrable dosage forms of drugs indicated to treat chronic clinical conditions has made a significant positive impact not only on the healthcare expenses borne by patients but also on compliance to prescribed therapeutic regimens. As the number of patients suffering from such disorders increase, the demand for more convenient and patient friendly drug delivery solutions is also on the rise.

Scope of the Report:

The ‘Prefilled Syringes Market (5th edition), 2019-2030' report features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market landscape of companies engaged in manufacturing prefilled syringes, providing information on year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume.
  • An overview of the current market landscape of companies that are developing drugs in combination with prefilled syringes, featuring information on year of establishment, company size, geographical location of the developers, target indication, phases of development, type of drug molecule, route of administration, approval year (for marketed products), dosage details (for marketed products) and other approved dosage forms (for marketed products).
  • A detailed competitiveness analysis of the various prefilled syringes that we came across, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with prefilled syringes in the near future, shortlisted based on an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development) based on different parameters, such as pipeline strength, target therapeutic indication(s) and developer strength.
  • An analysis of the various prefilled syringe combination product-related initiatives of big pharma players, based on parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and likely future adoption (based on potential injectable product candidates in the pipeline that are likely to be delivered via prefilled syringes), target therapeutic area(s) and type of drug molecule.
  • A review of the landscape of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider.
  • A detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies involved in developing and manufacturing such solutions.
  • An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.
  • Brief discussions of currently available specialty syringes, which include prefilled flush syringes, prefilled diluent syringe systems and prefilled contrast agent delivery systems.
  • A case study on companies that are engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.
  • Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent prefilled syringe component manufacturers, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as the number of commercialized combination products, annual adoption rate, and expected pricing, we have provided an informed estimate of the likely evolution of the market over the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] therapeutic area (blood disorders, infectious diseases, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals)
  • Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
  • Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services)
  • Marco Pederiva (Marketing & Sales Director, Lonstroff)
  • Anonymous (Chief Executive Officer, Small-sized Medical Device Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringes market in the mid to long term.

Chapter 3 provides an introduction to the concept of prefilled syringes, including details on their origin, various affiliated components (such as barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap), fabrication material (glass and plastic), manufacturing-related information, and other critical attributes and features. In addition, the chapter includes a discussion highlighting the future of prefilled syringes.

Chapter 4 provides an overview of around 80 prefilled syringes that are available in the market and provides details on the companies that manufacture such products. It features analyses of the prefilled syringes, based on various parameters, such as type of material (glass and plastic), number of barrel chambers (dual chamber and single chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes a discussion on the technological advances of prefilled syringes that have taken place in the recent past.

Chapter 5 presents a product competitiveness analysis of glass and plastic prefilled syringes (separately) based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 includes detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter also features short profiles of some of the small and mid-sized manufacturers, highlighting brief overview of the company, product portfolio and recent developments (if available).

Chapter 7 highlights the growing concerns associated with needlestick injuries and the various steps (including regional and global legislations) that have been taken to prevent sharps related mishaps. One of the important risk mitigation strategies covered in this chapter is the installation of safety features in upcoming versions of prefilled syringes. In addition, the chapter provides information on syringe-related safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 8 presents overview of the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the prefilled syringes regulatory requirements and the role of regulatory bodies in the approval of syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 9 provides details on the various pipeline and approved products that are being tested or available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. It features a detailed analysis of these drugs, based on the various parameters, such as the target therapeutic area(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes case studies of top two marketed drugs available in prefilled syringes, namely Humira® and Enbrel®.

Chapter 10 features a discussion on the most commonly targeted therapeutic indications, including information on the approved / marketed injectable drug products available for the treatment of such clinical conditions (across different target therapeutic areas) and their respective biosimilars.

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via prefilled syringes in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a prefilled syringe in the future was estimated using the weighted average method. Additionally, the chapter features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringes manufacturers, based on multiple parameters, such as pipeline strength, targeted therapeutic indications, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to develop combination products.

Chapter 12 highlights top ten big pharma players engaged or likely to be engaged in the domain of prefilled syringes. It features a benchmarking of the companies based on parameters, such as current adoption (based on number of approved and development-stage prefilled syringe combination products) and likely future adoption (based on potential likely early and late stage pipelines), target therapeutic area(s), and type of drug molecules.

Chapter 13 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and prefilled contrast agent delivery systems. For each type of specialty syringe, we have provided a brief overview and details on the different products that are available in the market and their advantages.

Chapter 14 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advancements in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual chambered syringe systems. The chapter also highlights novel lubrication and sterilization technologies.

Chapter 15 presents an insightful market forecast analysis, highlighting the future potential of the prefilled syringes market till the year 2030. We have segregated the opportunity of the market on the basis of [A] therapeutic area (blood disorders, infectious diseases, autoimmune disorders, oncology disorders, neurological disorders, ophthalmic diseases and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). The analysis presents 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 16 features a detailed discussion on the various factors that are anticipated to drive growth within the prefilled syringes market, such as the rise in preference for self-administration of medication, increase in incidence of chronic diseases, evolving patient landscape, introduction and growing adoption of biologics / biosimilars, initiatives focused on the prevention of needlestick injuries and the various potential applications of prefilled syringes.

Chapter 17 provides a detailed SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 18 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler, Lonstroff, Ompi, West Pharmaceutical and Jiangsu Hualan New Pharmaceutical Material.

Chapter 19 provides an overview of the landscape of pharmaceutical companies that offer fill / finish contract services for prefilled syringes. It includes information related to over 100 contract service providers that are currently active in this domain. It features in-depth analyses based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of drug molecules filled (small molecule and biologics), year of establishment, company size and geographical location of the service providers.

Chapter 20 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Elcam Medical, Nuance Designs, Owen Mumford, SHL Group, Union Medico and Ypsomed.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is a collection of transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringes manufacturing domain. In this chapter, we have presented the details of our conversations with Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical), Marco Pederiva (Marketing & Sales Director, Lonstroff) and Anonymous (Chief Executive Officer, Small-sized Medical Device Company).

Chapters 23 is an appendix that provides tabulated data and numbers for all the figures included in the report.

Chapter 24 is an appendix that contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1 PREFACE

  • 1.1. Chapter Overview
  • 1.2. Scope of the Report
  • 1.3. Research Methodology
  • 1.4. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION TO PREFILLED SYRINGES

  • 3.1. Chapter Overview
  • 3.2. History of Prefilled Syringes
  • 3.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices
    • 3.3.1. Benefits for Healthcare Professionals and End Users
    • 3.3.2. Benefits to Manufacturers
    • 3.3.3. Shift from Existing Dosage Forms to Prefilled Syringes
  • 3.4. Prefilled Syringe Components
  • 3.5. Classification of Prefilled Syringes
    • 3.5.1. Classification by Barrel Fabrication Material
      • 3.5.1.1. Glass
        • 3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
        • 3.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes
      • 3.5.1.2. Plastic
        • 3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
        • 3.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
        • 3.5.1.2.3. Factors Likely to Drive the Use of Plastic Barrel Prefilled Syringes
    • 3.5.2. Classification by Number of Chambers in the Barrel
    • 3.5.3. Classification by Type of Needle System
    • 3.5.4. Classification by Type of Packaging
  • 3.6. Critical Attributes of Prefilled Syringe Design
  • 3.7. Manufacturing Prefilled Syringes
    • 3.7.1. Production of Barrels
      • 3.7.1.1. Glass Barrel Prefilled Syringes
      • 3.7.1.2. Plastic Barrel Prefilled Syringes
    • 3.7.2. Production of Syringes
    • 3.7.3. Barrel Siliconization
    • 3.7.4. Syringe Sterilization
    • 3.7.5. Validation of Sterilization
    • 3.7.6. Syringe Filling
    • 3.7.7. Syringe Testing
  • 3.8. Future of Prefilled Syringes

4 PREFILLED SYRINGES: MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Prefilled Syringes: List of Available / Under Development Devices
    • 4.2.1. Analysis by Type of Barrel Fabrication Material
    • 4.2.2. Analysis by Number of Barrel Chambers
    • 4.2.3. Analysis by Type of Needle System
    • 4.2.4. Analysis by Device Capacity
  • 4.3. Prefilled Syringes: List of Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Geographical Location of Headquarters
    • 4.3.4. Analysis by Geographical Location of Manufacturing Facilities
  • 4.4. Technological Developments in Prefilled Syringes

5 PRODUCT COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions and Key Parameters
  • 5.4. Product Competitiveness Analysis: Prefilled Syringe Systems
    • 5.4.1. Glass Barrel Prefilled Syringes
    • 5.4.2. Plastic Barrel Prefilled Syringes

6 MANUFACTURERS OF PREFILLED SYRINGES

  • 6.1. Chapter Overview
  • 6.2. Key Prefilled Syringe Manufacturers Based in North America
    • 6.2.1. Becton Dickinson
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Prefilled Technology Solutions
      • 6.2.1.4. Glass Barrel Prefilled Systems
        • 6.2.1.4.1. BD Hypak Prefilled Syringe
        • 6.2.1.4.2. BD Neopak Prefilled Syringe
        • 6.2.1.4.3. BD Hylok Prefilled Syringe
      • 6.2.1.5. Plastic Barrel Prefilled Systems
        • 6.2.1.5.1. BD Sterifill Syringe Systems
      • 6.2.1.6. Other Prefilled Delivery Systems
        • 6.2.1.6.1. BD Uniject
      • 6.2.1.7. Recent Developments
      • 6.2.1.8. Future Outlook
    • 6.2.2. West Pharmaceutical
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Prefilled Technology Solutions
      • 6.2.2.4. Plastic Barrel Prefilled Systems
        • 6.2.2.4.1. Daikyo Crystal Zenith Polymer RTU Prefilled Syringe
      • 6.2.2.5. Drug Reconstitution Systems
      • 6.2.2.6. Recent Developments
      • 6.2.2.7. Future Outlook
  • 6.3. Key Prefilled Syringe Manufacturers Based in Europe
    • 6.3.1. Gerresheimer
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Prefilled Technology Solutions
      • 6.3.1.4. Glass Barrel Prefilled Systems
        • 6.3.1.4.1. Gx Glass Syringes
      • 6.3.1.5. Plastic Barrel Prefilled Systems
        • 6.3.1.5.1. ClearJect Prefilled syringes
        • 6.3.1.5.2. Gx RTF Clearject Needle Syringe
      • 6.3.1.6. Safety Syringes
        • 6.3.1.6.1. Gx InnoSafe Safety Syringes
      • 6.3.1.7. Self-Injection Devices
      • 6.3.1.8. Recent Developments
      • 6.3.1.9. Future Outlook
    • 6.3.2. Ompi
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Glass Barrel Prefilled Systems
        • 6.3.2.3.1. EZ-Fill Syringes
          • 6.3.2.3.1.1. EZ-fill Fina
          • 6.3.2.3.1.2. EZ-fill Nexa
          • 6.3.2.3.1.3. EZ-fill Alba
      • 6.3.2.4. Recent Developments
      • 6.3.2.5. Future Outlook
    • 6.3.3. SCHOTT
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Glass Barrel Prefilled Syringes
        • 6.3.3.3.1. syriQ Glass Syringes
      • 6.3.3.4. Plastic Barrel Prefilled Syringes
        • 6.3.3.4.1. TopPac Polymer Syringes
      • 6.3.3.5. Recent Developments
      • 6.3.3.6. Future Outlook
  • 6.4. Key Prefilled Syringe Manufacturers in Asia
    • 6.4.1. Nipro (Acquired MGlas)
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Glass Barrel Prefilled Systems
      • 6.4.1.4. Recent Developments
      • 6.4.1.5. Future Outlook
    • 6.4.2. WEGO Prefills Pharmaceutical Packaging
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. WeGo Glass Prefilled Syringe
      • 6.4.2.4. Weigao Prefilled Flush Syringes
      • 6.4.2.5. Future Outlook
    • 6.4.3. Taisei Kako
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Glass Barrel Prefilled Systems
        • 6.4.3.2.1. VF-Syringe
        • 6.4.3.2.1. SIN-Syringe
      • 6.4.3.3. Plastic Barrel Prefilled System
        • 6.4.3.3.1. ClearJect Syringes
        • 6.4.3.3.2. FULJECT Passive Type Syringe
        • 6.4.3.3.3. Ajex Needleless Injection System
      • 6.4.3.4. Future Outlook
    • 6.4.4. Terumo
      • 6.4.4.1. Company Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Plastic Barrel Prefilled Syringe
      • 6.4.4.4. Safety Devices: Add-On Devices
      • 6.4.4.5. Recent Developments
      • 6.4.4.6. Future Outlook
  • 6.5. Other Manufacturers
    • 6.5.1. Aguettant
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Prefilled Syringe Portfolio
        • 6.5.1.2.1. Aguettant Prefilled Syringe
      • 6.5.1.3. Recent Developments
    • 6.5.2. Arte
      • 6.5.2.1. Company Overview
      • 6.5.2.2. Prefilled Syringe Portfolio
        • 6.5.2.2.1. Dual Chamber Prefillable Syringe
        • 6.5.2.2.2. Single Chamber Prefillable Syringe
    • 6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)
      • 6.5.3.1. Company Overview
      • 6.5.3.2. Prefilled Syringe Portfolio
    • 6.5.4. Pfizer Injectables
      • 6.5.4.1. Company Overview
      • 6.5.4.2. Prefilled Syringe Portfolio
        • 6.5.4.2.1. ABBOJECT Syringe
        • 6.5.4.2.2. Emergency Syringes
        • 6.5.4.2.3. iSecure Syringe System
    • 6.5.5. Shandong Pharmaceutical Glass
      • 6.5.5.1. Company Overview
      • 6.5.5.2. Prefilled Syringe Portfolio
    • 6.5.6. Shandong Zibo Minkang Pharmaceutical packing
      • 6.5.6.1. Company Overview
      • 6.5.6.2. Prefilled Syringe Portfolio
    • 6.5.7. Vetter Pharma
      • 6.5.7.1. Company Overview
      • 6.5.7.2. Prefilled Syringe Portfolio
        • 6.5.7.2.1. Lyo-Ject Glass Prefilled Syringe
        • 6.5.7.2.2. Vetter-Ject Safety Device
        • 6.5.7.2.3. V-OVS Safety Device
      • 6.5.7.3. Recent Developments

7. NEEDLESTICK INJURIES

  • 7.1. Chapter Overview
  • 7.2. Incidence and Associated Financial Burden
  • 7.3. Government Legislations for Prevention of Needlestick Injuries
  • 7.4. Safety Mechanisms Used in Modern Prefilled Syringes
    • 7.4.1. Safety Systems: Add-On Safety Device Manufacturers
      • 7.4.1.1. Becton Dickinson
      • 7.4.1.2. Catalent
      • 7.4.1.3. Terumo
      • 7.4.1.4. Tip-Top
      • 7.4.1.5. West Pharmaceutical
    • 7.4.2. Safety Systems: Integrated Safety Device Manufacturers
      • 7.4.2.1. Gerresheimer
      • 7.4.2.2. Injecto
      • 7.4.2.3. MedicalChain International
      • 7.4.2.4. OMPI
      • 7.4.2.5. Owen Mumford
      • 7.4.2.6. SHL Group
      • 7.4.2.7. Taisei Kako

8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES

  • 8.1. Chapter Overview
  • 8.2. Regulatory Approval of Combination Products in the US
    • 8.2.1. Overview
    • 8.2.2. Historical Background
    • 8.2.3. Regulatory Bodies and their Role in Product Approval
    • 8.2.4. Regulatory Approval for Prefilled Syringes
  • 8.3. Regulatory Approval of Combination Products in Europe
    • 8.3.1. Overview
    • 8.3.2. Regulatory Bodies and their Role in Product Approval
    • 8.3.3. Regulatory Approval for Prefilled Syringes
  • 8.4. Regulatory Approval of Combination Products in Canada
    • 8.4.1. Overview
    • 8.4.2. Regulatory Bodies and their Role in Product Approval
    • 8.4.3. Regulatory Approval for Prefilled Syringes
  • 8.5. Regulatory Approval of Combination Products in Brazil
    • 8.5.1. Overview
    • 8.5.2. Regulatory Bodies and their Role in Product Approval
    • 8.5.3. Regulatory Approval for Prefilled Syringes
  • 8.6. Regulatory Approval of Combination Products in Mexico
    • 8.6.1. Overview
    • 8.6.2. Regulatory Bodies and their Role in Product Approval
    • 8.6.3. Regulatory Approval for Prefilled Syringes
  • 8.7. Regulatory Approval of Combination Products in Argentina
    • 8.7.1. Overview
    • 8.7.2. Regulatory Bodies and their Role in Product Approval
    • 8.7.3. Regulatory Approval for Prefilled Syringes
  • 8.8. Regulatory Approval of Combination Products in Australia
    • 8.8.1. Overview
    • 8.8.2. Regulatory Bodies and their Role in Product Approval
    • 8.8.3. Regulatory Approval for Prefilled Syringes
  • 8.9. Regulatory Approval of Combination Products in Japan
    • 8.9.1. Overview
    • 8.9.2. Regulatory Bodies and their Role in Product Approval
    • 8.9.3. Regulatory Approval for Prefilled syringes
  • 8.10. Regulatory Approval of Combination Products in China
    • 8.10.1. Overview
    • 8.10.2. Regulatory Bodies and their Role in Product Approval
    • 8.10.3. Regulatory Approval for Prefilled syringes
  • 8.11. Regulatory Approval of Combination Products in India
    • 8.11.1. Overview
    • 8.11.2. Regulatory Bodies and their Role in Product Approval
    • 8.11.3. Regulatory Approval for Prefilled Syringes
  • 8.12. Regulatory Approval of Combination Products in South Korea
    • 8.12.1. Overview
    • 8.12.2. Regulatory Bodies and their Role in Product Approval
    • 8.12.3. Regulatory Approval for Prefilled Syringes
  • 8.13. Regulatory Approval of Combination Products in Saudi Arabia
    • 8.13.1. Overview
    • 8.13.2. Regulatory Bodies and their Role in Product Approval
    • 8.13.3. Regulatory Approval for Prefilled Syringes
  • 8.14. Regulatory Approval of Combination Products in United Arab Emirates
    • 8.14.1. Overview
    • 8.14.2. Regulatory Bodies and their Role in Product Approval
    • 8.14.3. Regulatory Approval for Prefilled Syringes

9. PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW

  • 9.1. Chapter Overview
  • 9.2. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
    • 9.2.1. Analysis by Type of Drug Molecule
    • 9.2.2. Analysis by Approval Year
    • 9.2.3. Analysis by Route of Administration
    • 9.2.4. Analysis by Target Therapeutic Area
    • 9.2.5. Prefilled Syringe Combination Products: Additional Information
      • 9.2.5.1. Analysis by Dose Strength
      • 9.2.5.2. Analysis by Other Approved Dosage Forms
  • 9.3. Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2019
    • 9.3.1. Analysis by Type of Drug Molecule
    • 9.3.2. Analysis by Phase of Development
    • 9.3.3. Analysis by Route of Administration
    • 9.3.4. Analysis by Target Therapeutic Area
  • 9.4. Prefilled Syringe Combination Products: List of Developers
    • 9.4.1. Analysis by Year of Establishment
    • 9.4.2. Analysis by Company Size
    • 9.4.3. Analysis by Geographical Location of Headquarters
  • 9.5. Leading Drugs in Prefilled Syringes
  • 9.6. Other Drugs Available in Prefilled Syringes
  • 9.7. Popular Drugs in Prefilled Syringes: Case Studies
    • 9.7.1. HUMIRA® (Adalimumab), AbbVie / Eisai
      • 9.7.1.1. Target Indications and Available Dosage Forms
      • 9.7.1.2. Shift from Vials to Syringes
    • 9.7.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
      • 9.7.2.1. Target Indications and Available Dosage Forms
      • 9.7.2.2. Shift from Vials to Syringes

10 KEY THERAPEUTIC AREAS

  • 10.1. Chapter Overview
    • 10.1.1. Autoimmune Disorders
      • 10.1.1.1. Approved Injectables
      • 10.1.1.2. Biosimilars
    • 10.1.2. Infectious Diseases
      • 10.1.2.1. Antiviral Drugs
        • 10.1.2.1.1. Approved Injectables
        • 10.1.2.1.2. Biosimilars
      • 10.1.2.2. Vaccines
        • 10.1.2.2.1. Approved Injectables
    • 10.1.3. Neurological Disorders
      • 10.1.3.1. Approved Injectables
      • 10.1.3.2. Biosimilars
    • 10.1.4. Metabolic Disorders
      • 10.1.4.1. Approved Injectables
      • 10.1.4.2. Biosimilars

11 PREFILLED SYRINGES LIKELY DRUG CANDIDATES AND PARTNER ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Likely Drug Candidates
    • 11.2.1. Methdology and Key Parameters
  • 11.3. Marketed Drug Candidates
    • 11.3.1. Most Likely Candidates for Delivery via Prefilled Syringes
    • 11.3.2. Likely Candidates for Delivery via Prefilled Syringes
    • 11.3.3. Less Likely Candidates for Delivery via Prefilled Syringes
    • 11.3.4. Least Likely Candidates for Delivery via Prefilled Syringes
  • 11.4. Clinical Drug Candidates
    • 11.4.1. Most Likely Candidates for Delivery via Prefilled Syringes
    • 11.4.2. Likely Candidates for Delivery via Prefilled Syringes
    • 11.4.3. Less Likely Candidates for Delivery via Prefilled Syringes
    • 11.4.4. Least Likely Candidates for Delivery via Prefilled Syringes
  • 11.5. Potential Strategic Partners
    • 11.5.1. Methodology and Key Parameters
    • 11.5.2. Opportunities in North America
      • 11.5.2.1. Most Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.2.2. Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.2.3. Less Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.2.4. Least Likely Partners for Prefilled Syringes Combination Product Development
    • 11.5.3. Opportunities in Europe
      • 11.5.3.1. Most Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.3.2. Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.3.3. Less Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.3.4. Unlikely Partners for Prefilled Syringes Combination Product Development
    • 11.5.4. Opportunities in Asia-Pacific and Rest of the World
      • 11.5.4.1. Most Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.4.2. Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.4.3. Less Likely Partners for Prefilled Syringes Combination Product Development
      • 11.5.4.4. Least Likely Partners for Prefilled Syringes Combination Product Development

12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES

  • 12.1. Chapter Overview
  • 12.2. Methdology
  • 12.3. Top Pharmaceutical Companies
    • 12.3.1. Analysis by Therapeutic Area
      • 12.3.1.1. Autoimmune Disorders
      • 12.3.1.2. Infectious Diseases
      • 12.3.1.3. Oncological Disorders
      • 12.3.1.4. Metabolic Disorders
      • 12.3.1.5. Neurological Disorders
      • 12.3.1.6. Inflammatory Disorders
      • 12.3.1.7. Orthopedic Disorders
      • 12.3.1.8. Others
    • 12.3.2. Analysis by Type of Molecule
      • 12.3.2.1. Antibodies
      • 12.3.2.2. Vaccines
      • 12.3.2.3. Proteins
      • 12.3.2.4. Others

13 SPECIALTY PREFILLED SYRINGES

  • 13.1. Chapter Overview
  • 13.2. Prefilled Flush Syringes
    • 13.2.1. Overview
    • 13.2.2. Prefilled Flush Syringes Available in the Market
    • 13.2.3. Advantages of Prefilled Flush Syringes
  • 13.3. Prefilled Diluent Syringes
    • 13.3.1. Overview
    • 13.3.2. Lyophilized Drugs Available in Prefilled Diluent Syringes
    • 13.3.3. Advantages of Prefilled Diluent Syringes
  • 13.4. Contrast Agent Prefilled Syringes
    • 13.4.1. Overview
    • 13.4.2. Contrast Agents Available in Prefilled Syringes
    • 13.4.3. Advantages of Contrast Agent Prefilled Syringes

14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES

  • 14.1. Chapter Overview
  • 14.2. Prefilled Syringes For Lyophilized Drugs
    • 14.2.1. Prefilled Diluent Syringes
    • 14.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes
      • 14.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringes
      • 14.2.2.2. Prefilled Dual-Chambered Prefilled Pen Injectors for Lyophilized Drugs
  • 14.3. Prefilled Syringes for Ophthalmic Delivery
  • 14.4. Prefilled Syringes for Dermal Fillers
  • 14.5. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
  • 14.6. Prefilled Syringes with Low Particle Formation Risk
  • 14.7. Lubrication Technology for Prefilled Syringes
  • 14.8. Advances in Terminal Sterilization of Prefilled Syringes
    • 14.8.1. Noxilizer's Nitrogen Dioxide Sterilization Technology
  • 14.9. Prefilled Syringes Usage Aids for Patients and Healthcare Providers

15 MARKET SIZING AND OPPORTUNITY ANALYSIS15.1. Chapter Overview

  • 15.2. Scope and Methodology
  • 15.3. Global Prefilled Syringes Market, 2020-2030
    • 15.3.1. Prefilled Syringes Market: Distribution by Therapeutic Area
      • 15.3.1.1. Prefilled Syringes Market: Autoimmune Disorders
      • 15.3.1.2. Prefilled Syringes Market: Infectious Diseases
      • 15.3.1.3. Prefilled Syringes Market: Neurological Disorders
      • 15.3.1.4. Prefilled Syringes Market: Blood Disorders
      • 15.3.1.5. Prefilled Syringes Market: Oncological Disorders
      • 15.3.1.6. Prefilled Syringes Market: Psychiatric Diseases
      • 15.3.1.7. Prefilled Syringes Market: Respiratory Disorders
      • 15.3.1.8. Prefilled Syringes Market: Cardiovascular Disorders
      • 15.3.1.9. Prefilled Syringes Market: Metabolic Disorders
      • 15.3.1.10. Prefilled Syringes Market: Ophthalmic Disorder
      • 15.3.1.11. Prefilled Syringes Market: Orthopedic Disorders
      • 15.3.1.12. Prefilled Syringes Market: Other Diseases
    • 15.3.2. Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material
      • 15.3.2.1. Prefilled Syringes Market: Glass Barrel Prefilled Syringes
      • 15.3.2.2. Prefilled Syringes Market: Plastic Barrel Prefilled Syringes
    • 15.3.3. Prefilled Syringes Market: Distribution by Type of Chamber System
      • 15.3.3.1. Prefilled Syringes Market: Single Chamber Prefilled Syringes
      • 15.3.3.2. Prefilled Syringes Market: Dual Chamber Prefilled Syringes
    • 15.3.4. Prefilled Syringes Market: Distribution by Type of Drug Molecule
      • 15.3.4.1. Prefilled Syringes Market: Antibodies
      • 15.3.4.2. Prefilled Syringes Market: Proteins
      • 15.3.4.3. Prefilled Syringes Market: Peptides
      • 15.3.4.4. Prefilled Syringes Market: Small Molecules
      • 15.3.4.5. Prefilled Syringes Market: Vaccines
    • 15.3.5. Prefilled Syringes Market: Distribution by Geography
      • 15.3.5.1. Prefilled Syringes Market: North America
      • 15.3.5.2. Prefilled Syringes Market: Europe
      • 15.3.5.3. Prefilled Syringes Market: Asia Pacific
      • 15.3.5.4. Prefilled Syringes Market: Latin America
      • 15.3.5.5. Prefilled Syringes Market: Middle East and Africa
    • 15.3.6. Prefilled Syringes Market: Distribution by Specialty Syringes
    • 15.3.7. Prefilled Syringes Market for Autoimmune Disorders
      • 15.3.7.1. Distribution by Syringe Barrel Material
        • 15.3.7.1.1. Glass Barrel Prefilled Syringes
        • 15.3.7.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.7.2. Distribution by Type of Chamber System
        • 15.3.7.2.1. Single Chamber Prefilled Syringes
        • 15.3.7.2.2. Dual Chamber Prefilled Syringes
      • 15.3.7.3. Distribution by Type of Drug Molecule
        • 15.3.7.3.1. Antibodies
        • 15.3.7.3.2. Proteins
        • 15.3.7.3.3. Small Molecules
      • 15.3.7.4. Distribution by Geography
        • 15.3.7.4.1. North America
        • 15.3.7.4.2. Europe
        • 15.3.7.4.3. Asia Pacific
        • 15.3.7.4.4. Latin America
        • 15.3.7.4.5. Middle East and Africa
    • 15.3.8. Prefilled Syringes Market For Infectious Disorders
      • 15.3.8.1. Distribution by Type of Syringe Barrel Material
        • 15.3.8.1.1. Glass Barrel Prefilled Syringes
        • 15.3.8.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.8.2. Distribution by Type of Chamber System
        • 15.3.8.2.1. Single Chamber Prefilled Syringes
        • 15.3.8.2.2. Dual Chamber Prefilled Syringes
      • 15.3.8.3. Distribution by Type of Drug Molecule
        • 15.3.8.3.1. Vaccines
      • 15.3.8.4. Distribution by Geography
        • 15.3.8.4.1. North America
        • 15.3.8.4.2. Europe
        • 15.3.8.4.3. Asia Pacific
        • 15.3.8.4.4. Latin America
        • 15.3.8.4.5. Middle East and Africa
    • 15.3.9. Prefilled Syringes Market For Neurological Disorders
      • 15.3.9.1. Distribution by Type of Syringe Barrel Material
        • 15.3.9.1.1. Glass Barrel Prefilled Syringes
        • 15.3.9.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.9.2. Distribution by Type of Chamber System
        • 15.3.9.2.1. Single Chamber Prefilled Syringes
        • 15.3.9.2.2. Dual Chamber Prefilled Syringes
      • 15.3.9.3. Distribution by Type of Drug Molecule
        • 15.3.9.3.1. Antibodies
        • 15.3.9.3.2. Proteins
        • 15.3.9.3.3. Peptides
      • 15.3.9.4. Distribution by Geography
        • 15.3.9.4.1. North America
        • 15.3.9.4.2. Europe
        • 15.3.9.4.3. Asia Pacific
        • 15.3.9.4.4. Latin America
        • 15.3.9.4.5. Middle East and Africa
    • 15.3.10. Prefilled Syringes Market For Blood Disorders
      • 15.3.10.1. Distribution by Type of Syringe Barrel Material
        • 15.3.10.1.1. Glass Barrel Prefilled Syringes
        • 15.3.10.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.10.2. Distribution by Type of Chamber System
        • 15.3.10.2.1. Single Chamber Prefilled Syringes
        • 15.3.10.2.2. Dual Chamber Prefilled Syringes
      • 15.3.10.3. Distribution by Type of Drug Molecule
        • 15.3.10.3.1. Proteins
        • 15.3.10.3.2. Small Molecules
      • 15.3.10.4. Distribution by Geography
        • 15.3.10.4.1. North America
        • 15.3.10.4.2. Europe
        • 15.3.10.4.3. Asia Pacific
        • 15.3.10.4.4. Latin America
        • 15.3.10.4.5. Middle East and Africa
    • 15.3.11. Prefilled Syringes Market For Oncological Disorders
      • 15.3.11.1. Distribution by Type of Syringe Barrel Material
        • 15.3.11.1.1. Glass Barrel Prefilled Syringes
        • 15.3.11.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.11.2. Distribution by Type of Chamber System
        • 15.3.11.2.1. Single Chamber Prefilled Syringes
        • 15.3.11.2.2. Dual Chamber Prefilled Syringes
      • 15.3.11.3. Distribution by Type of Drug Molecule
        • 15.3.11.3.1. Antibodies
        • 15.3.11.3.2. Proteins
        • 15.3.11.3.3. Peptides
        • 15.3.11.3.4. Small Molecules
        • 15.3.11.3.5. Vaccines
      • 15.3.11.4. Distribution by Geography
        • 15.3.11.4.1. North America
        • 15.3.11.4.2. Europe
        • 15.3.11.4.3. Asia Pacific
        • 15.3.11.4.4. Latin America
        • 15.3.11.4.5. Middle East and Africa
    • 15.3.12. Prefilled Syringes Market For Metabolic Disorders
      • 15.3.12.1. Distribution by Type of Syringe Barrel Material
        • 15.3.12.1.1. Glass Barrel Prefilled Syringes
        • 15.3.12.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.12.2. Distribution by Type of Chamber System
        • 15.3.12.2.1. Single Chamber Prefilled Syringes
        • 15.3.12.2.2. Dual Chamber Prefilled Syringes
      • 15.3.12.3. Distribution by Type of Drug Molecule
        • 15.3.12.3.1. Proteins
        • 15.3.12.3.2. Peptides
      • 15.3.12.4. Distribution by Geography
        • 15.3.12.4.1. North America
        • 15.3.12.4.2. Europe
        • 15.3.12.4.3. Asia Pacific
        • 15.3.12.4.4. Latin America
        • 15.3.12.4.5. Middle East and Africa
    • 15.3.13. Prefilled Syringes Market For Other Disorders
      • 15.3.13.1. Distribution by Type of Syringe Barrel Material
        • 15.3.13.1.1. Glass Barrel Prefilled Syringes
        • 15.3.13.1.2. Plastic Barrel Prefilled Syringes
      • 15.3.13.2. Distribution by Type of Chamber System
        • 15.3.13.2.1. Single Chamber Prefilled Syringes
        • 15.3.13.2.2. Dual Chamber Prefilled Syringes
      • 15.3.13.3. Distribution by Type of Drug Molecule
        • 15.3.13.3.1. Antibodies
        • 15.3.13.3.2. Proteins
        • 15.3.13.3.3. Peptides
        • 15.3.13.3.4. Small Molecules
      • 15.3.13.4. Distribution by Geography
        • 15.3.13.4.1. North America
        • 15.3.13.4.2. Europe
        • 15.3.13.4.3. Asia Pacific
        • 15.3.13.4.4. Latin America
        • 15.3.13.4.5. Middle East and Africa

16 GROWTH DRIVERS

  • 16.1. Chapter Overview
  • 16.2. Rising Incidence of Chronic Diseases
  • 16.3. Growing Preference for Self-Injection
  • 16.4. Evolving Patient Demographics
  • 16.5. Growth of Biologics and Biosimilars Market
  • 16.6. Changing Pharmaceutical Strategies
  • 16.7. Increasing Focus on Prevention of Needlestick Injuries
  • 16.8. Prefilled Syringes in Autoinjectors and Pen Injectors

17 SWOT ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Strengths
  • 17.3. Weaknesses
  • 17.4. Opportunities
  • 17.5. Threats
  • 17.6. Concluding Remarks

18 PREFILLED SYRINGE COMPONENT MANUFACTURERS

  • 18.1. Chapter Overview
  • 18.2. List of Component Manufacturers
  • 18.3. Aptar Pharma (a Part of AptarGroup)
    • 18.3.1. Company Overview
    • 18.3.2. Financial Performance
    • 18.3.3. Product Portfolio
    • 18.3.4. Recent Developments and Future Outlook
  • 18.4. West Pharmaceutical
    • 18.4.1. Company Overview
    • 18.4.2. Financial Performance
    • 18.4.3. Product Portfolio
    • 18.4.4. Recent Developments and Future Outlook
  • 18.5. Datwyler Sealing Solutions (a Part of Datwyler Group)
    • 18.5.1. Company Overview
    • 18.5.2. Financial Performance
    • 18.5.3. Product Portfolio
    • 18.5.4. Recent Developments and Future Outlook
  • 18.6. Lonstroff (a Part of Sumitomo Rubber Industries)
    • 18.6.1. Company Overview
    • 18.6.2. Financial Performance
    • 18.6.3. Product Portfolio
    • 18.6.4. Recent Developments and Future Outlook
  • 18.7. Ompi (a Part of Stevanato Group)
    • 18.7.1. Company Overview
    • 18.7.2. Product Portfolio
    • 18.7.3. Recent Developments and Future Outlook
  • 18.8. Jiangsu Hualan Pharmaceutical New Material
    • 18.8.1. Company Overview
    • 18.8.2. Product Portfolio
    • 18.8.3. Recent Developments and Future Outlook

19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES

  • 19.1. Chapter Overview
  • 19.2. Fill / Finish Processing of Prefilled Syringes
    • 19.2.1. Steps Involved in Fill / Finish Process
    • 19.2.2. Methods of Filling and Stoppering of Prefilled Syringes
    • 19.2.3. Prefilled Syringe Filling Technologies
  • 19.3. Outsourcing of Fill / Finish Operations
  • 19.4. Growth Considerations
  • 19.5. Prefilled Syringes: List of Fill / Finish Service Providers
    • 19.5.1. Analysis by Year of Establishment
    • 19.5.2. Analysis by Geographical Location of Headquarters and Type of Drug Molecule
    • 19.5.3. Analysis by Scale of Operation

20 CASE STUDY: AUTOINJECTORS

  • 20.1. Chapter Overview
  • 20.2. Autoinjectors: Market Overview
  • 20.3. Key Players
    • 20.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)
      • 20.3.1.1. Company Overview
      • 20.3.1.2. Product Portfolio
    • 20.3.2. Nuance Designs
      • 20.3.2.1. Company Overview
      • 20.3.2.2. Product Portfolio
    • 20.3.3. Owen Mumford
      • 20.3.3.1. Company Overview
      • 20.3.3.2. Product Portfolio
    • 20.3.4. Scandinavian Health Limited (SHL) Group
      • 20.3.4.1. Company Overview
      • 20.3.4.2. Product Portfolio
    • 20.3.5. Union Medico
      • 20.3.5.1. Company Overview
      • 20.3.5.2. Product Portfolio
    • 20.3.6. Ypsomed
      • 20.3.6.1. Company Overview
      • 20.3.6.2. Product Portfolio

21 CONCLUDING REMARKS

  • 21.1. Chapter Overview
  • 21.2. Key Takeaways

22 INTERVIEW TRANSCRIPTS

  • 22.1. Chapter Overview
  • 22.2. Oval Medical Technologies
    • 22.2.1. Company Snapshot
    • 22.2.2. Interview Transcript: Matthew Young, Founder and Chief Technology Officer
  • 22.3. Intas Pharmaceuticals
    • 22.3.1. Company Snapshot
    • 22.3.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer
  • 22.4. IDT Biologika
    • 22.4.1. Company Snapshot
    • 22.4.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
  • 22.5. West Pharmaceutical
    • 22.5.1. Company Snapshot
    • 22.5.2. Interview Transcript: Kevin Cancelliere and Tibor Hlobik, Marketing Directors
  • 22.6. Lonstroff
    • 22.6.1. Company Snapshot
    • 22.6.2. Interview Transcript: Marco Pederiva, Marketing and Sales Directors
  • 22.7. IDEO
    • 22.7.1. Company Snapshot
    • 22.7.2. Interview Transcript: Jesse Fourt, Design Director
  • 22.8. Small-sized Medical Device Company
    • 22.8.1. Interview Transcript: Anonymous, Chief Executive Officer

23 APPENDIX 1: TABULATED DATA

24 APPENDIX 2: LIST OF COMPANIES

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.